Early Progression Beyond First-line Chemoimmunotherapy in Follicular Lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) Study

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2024 Dec 19

PMID 39698333

Authors

Alberto Bavieri

Maria E Nizzoli

Alessandra Tucci

Vittorio R Zilioli

Jacopo Olivieri

Benedetta Bianchi

Mansueto G Rosaria

Ombretta Annibali

Alessia Bari

Gloria M Casaluci

Michele Cimminiello

Nicola Di Renzo

Federica Cavallo

Vicenzo Pavone

Clara Mannarella

Annalisa Arcari

Maggi Alessandro

Antonella Anastasia

Vittoria Tarantino

Antonino Neri

Massimo Gentile

Fortunato Morabito

Stefano Luminari

Affiliations

Soon will be listed here.

References

Tan D, Horning S, Hoppe R, Levy R, Rosenberg S, Sigal B . Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013; 122(6):981-7. PMC: 3739040. DOI: 10.1182/blood-2013-03-491514. View

Ghione P, Palomba M, Ghesquieres H, Bobillo S, Patel A, Nahas M . Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2022; 108(3):822-832. PMC: 9973479. DOI: 10.3324/haematol.2022.281421. View

Yoon S, Cho J, Kim W, Kim S . Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. J Cancer. 2021; 12(9):2488-2497. PMC: 8040724. DOI: 10.7150/jca.54434. View

Casulo C, Dixon J, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W . Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2021; 139(11):1684-1693. PMC: 9974165. DOI: 10.1182/blood.2020010263. View

Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus R, Seymour J . Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clin Lymphoma Myeloma Leuk. 2022; 23(1):40-48. DOI: 10.1016/j.clml.2022.09.003. View

Jacobsen E . Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022; 97(12):1638-1651. DOI: 10.1002/ajh.26737. View

Maurer M, Bachy E, Ghesquieres H, Ansell S, Nowakowski G, Thompson C . Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016; 91(11):1096-1101. PMC: 5073042. DOI: 10.1002/ajh.24492. View

Sarkozy C, Maurer M, Link B, Ghesquieres H, Nicolas E, Thompson C . Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2018; 37(2):144-152. PMC: 6366812. DOI: 10.1200/JCO.18.00400. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

10.

Moccia A, Schar S, Hayoz S, Pirosa M, Taverna C, Novak U . Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol. 2020; 192(6):1031-1034. DOI: 10.1111/bjh.17045. View

11.

Casulo C, Larson M, Lunde J, Habermann T, Lossos I, Wang Y . Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022; 9(4):e289-e300. PMC: 9297334. DOI: 10.1016/S2352-3026(22)00033-3. View

12.

Casulo C, Byrtek M, Dawson K, Zhou X, Farber C, Flowers C . Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. PMC: 4879714. DOI: 10.1200/JCO.2014.59.7534. View

13.

Teras L, DeSantis C, Cerhan J, Morton L, Jemal A, Flowers C . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459. DOI: 10.3322/caac.21357. View

14.

Alonso-Alvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodriguez G . Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017; 178(5):699-708. DOI: 10.1111/bjh.14831. View

15.

Muntanola A, Mozas P, Mercadal S, Huguet M, Bobillo S, Bastos-Oreiro M . Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br J Haematol. 2022; 200(3):306-314. DOI: 10.1111/bjh.18522. View

16.

Freeman C, Kridel R, Moccia A, Savage K, Villa D, Scott D . Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019; 134(9):761-764. DOI: 10.1182/blood.2019000258. View